Mark Ragosa, CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc (KNSA), sold 134,790 shares at $26.95 ($3.6M) on 2025-04-30, disclosed to the SEC on 2025-05-01.
Scheduled sale ($3.6M) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.61 | 42,000 | $1.1M | 29.7% |
| 2 | $26.95 | 21,254 | $573K | 15.8% |
| 3 | $26.95 | 21,254 | $573K | 15.8% |
| 4 | $27.80 | 25,141 | $699K | 19.3% |
| 5 | $27.80 | 25,141 | $699K | 19.3% |
| Total | $26.85 avg | 134,790 |
| $3.6M |
| 100% |
| Filing → |
| KNSA | SELL | 2026-01-09 | $503K | — | Filing → |
| KNSA | SELL | 2025-12-10 | $3.6M | — | Filing → |
| KNSA | SELL | 2025-11-14 | $815K | — | Filing → |